8-KEarnings & ResultsLeadership ChangesOther Events+1

ELI LILLY & Co 8-K Report, Financial Results (Oct 23, 2019)

Filed October 23, 2019For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on October 23, 2019, primarily to report its third-quarter and nine-month financial results for 2019. The filing highlights the company's operational performance and provides an update on executive changes and compensation plans. Investors should note the financial results as detailed in the accompanying press release (Exhibit 99.1), which offers unaudited operating results for the periods ending September 30, 2019, including non-GAAP financial measures and updated guidance for the full year 2019. These figures are crucial for understanding the company's recent financial health and future outlook. In addition to the financial results, the 8-K announces significant executive transitions. Enrique Conterno, a key leader serving as Senior Vice President and President of Lilly Diabetes and Lilly USA, will retire effective December 31, 2019. This departure marks the end of an era for a significant segment of the company's operations. Furthermore, the Compensation Committee has decided to terminate the Executive Officer Incentive Plan, effective January 1, 2020, due to changes in tax legislation (Section 162(m) of the Internal Revenue Code). While this specific plan is ending, executive officers will continue to participate in the Eli Lilly and Company Bonus Plan.

Key Highlights

  • 1Eli Lilly announced its third-quarter and nine-month financial results for 2019, detailed in an attached press release (Exhibit 99.1).
  • 2The company provided unaudited operating results for the periods ending September 30, 2019, including non-GAAP financial measures.
  • 3Updated financial guidance for the full year 2019 was provided, offering insight into the company's expected performance.
  • 4Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, announced his retirement, effective December 31, 2019.
  • 5The Executive Officer Incentive Plan, previously designed for tax deductibility under Section 162(m), will be terminated effective January 1, 2020.
  • 6The termination of the incentive plan is a response to changes in Section 162(m) brought about by the Tax Cuts and Jobs Act of 2017.
  • 7Executive officers will continue to participate in the Eli Lilly and Company Bonus Plan.

Frequently Asked Questions